The use of gonadotropin-releasing hormone antagonist in ovarian stimulation

Clinical Obstetrics and Gynecology

Volumn 49, Issue 1, 2006, Pages 12-22

  Olivennes, F ^a  

^a Hopital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; CLOMIFENE CITRATE; GANIRELIX; GONADORELIN ANTAGONIST; GONADOTROPIN; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HEADACHE; HOT FLUSH; HUMAN; INJECTION SITE REACTION; INTRAUTERINE INSEMINATION; LUTEAL PHASE; OVARY FUNCTION; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; PREGNANCY RATE; REVIEW; STIMULATION; VAGINA BLEEDING; VAGINAL DRYNESS;

FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; LUTEINIZING HORMONE; MENSTRUAL CYCLE; OOCYTES; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY RATE;

EID: 33748621751     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.grf.0000197520.53682.32     Document Type: Review

References (76)

1. Liu HC, Lai YM, Davis O, et al. Improved pregnancy outcome with gonadotropin releasing hormone agonist (GnRH-a) stimulation is due to the improvement in oocyte quantity rather than quality. J Assist Reprod Genet. 1992;9:338-342.
2. Karten MJ, Hoeger CA, Hooh WA. The development of safer antagonists: strategy and status. In: Bouchard P, Haour F, Franchimont P, et al., eds. Recent Progress on LH-RH and Gonadal Peplides. Paris: Elsevier; 1990:147-158.
3. Dubourdieu S, Charbonnel B, d'Acremont MF, et al. Effect of a GNRH antagonist (Nal-Glu) during the periovulatory period: the LH surge requires secretion of gonadotropin-releasing hormone. J Clin Endocrinol Metab. 1994;78:343-347.
4. Olivennes F, Cunha-Filho JS, Fanchin R, et al. The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update. 2002;8:279-290.
5. Diedrich K, Diedrich E, Santos E, et al. Suppression of the endogenous LH-surge by the GNRH antagonist Cetrorelix during ovarian stimulation. Hum Reprod. 1994;9:788-791.
6. Albano C, Smitz J, Camus M, et al. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril. 1997;67:917-922.
7. The Ganirelix Dose-Finding Study Group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod. 1998;13:3023-3031.
8. Olivennes F, Fanchin R, Bouchard P, et al. The single or dual administration of the gonadotrophin-releasing hormone antagonist Cetrorelix in an in vitro fertilization embryo transfer program. Fertil Steril. 1994;62:468-476.
9. Olivennes F, Fanchin R, Rongieres-Bertrabd C, et al. GnRH antagonist in single dose applications. Clinics of North America. 2001;12:119-127.
10. Frydman R, Cornel C, de Ziegler D, et al. Prevention of premature luteinizing hormone and progesterone rise with a GNRH antagonist Nal-Glu in controlled ovarian hyperstimulation. Fertil Steril. 1991;56:923-927.
11. Frydman R, Cornel C, de Ziegler D, et al. Spontaneous luteinizing hormone surges can be reliably prevented by the timely administration of a gonadotrophin releasing hormone antagonist (Nal-Glu) during the late follicular phase. Hum Reprod. 1992;7:930-933.
12. Olivennes F, Alvarez S, Bouchard P, et al. The use of a new GNRH antagonist (Cetrorelix) in IVF-ETwith a single dose protocol: a dose finding study of 3 versus 2 mg. Hum Reprod. 1998a;13:2411-2414.
13. Christin-Maitre S, Olivennes F, Dubourdieu S, et al. Effect of GnRH antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation. Clin Endocrinol. 2000;52:721-726.
14. Olivennes F, Belaisch-Allart J, Emperaire JC, et al. A prospective randomized controlled study in IVF-ET with a single dose of a LH-RH antagonist (Cetrorelix) or a depot formula of a LH-RH agonist (triptorelin). Fertil Steril. 2000;73:314-320.
15. De Jong D, Macklon NS, Eijkemans MJ, et al. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon). Fertil Steril. 2001a;75:688-693.
16. Lindheim SR, Morales AJ. GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles. Hum Reprod. 2003;18:2048-2051.
17. Shapiro DB, Mitchell-Leef D, Carter M, et al. Ganirelix acetate use in normal- and poor-prognosis patients and the impact of estradiol patterns. Fertil Steril. 2005;83:666-670.
18. Felberbaum R, Reissmann T, Kupker W, et al. Hormone profiles under ovarian stimulation with human menopausal gonadotrophin (HMG) and concomitant administration of the gonadotropin releasing hormone GnRH-antagonist Cetrorelix at different dosages. J Assist Reprod Genet. 1996;13:216-222.
19. Albano C, Felberbaum RE, Smitz J, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist Cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod. 2000;15:526-531.
20. Borm G, Mannaerts B; The European Orgalutran Study Group. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod. 2000;15:1490-1498.
21. The North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 2001;75:38-45.
22. The European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod. 2001;16:644-651.
23. Ludwig M, Felberbaum RE, Devroey P, et al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Arch Gynecol Obstet. 2000;264:29-32.
24. Wikland M, Bergh C, Borg K, et al. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with Cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Hum Reprod. 2001;16:1676-1681.
25. Nikolettos N, Al-Hasani S, Felberbaum R, et al. Comparison of cryopreservation outcome with human pronuclear stage oocytes obtained by the GnRH antagonist, Cetrorelix, and GnRH agonist. Eur J Obstet Gynecol Reprod Biol. 2000;93:91-95.
26. Olivennes F, Frydman R. 'Friendly IVF' the way of the future? Hum Reprod. 1998b;13:1121-1124.
27. Engel JB, Ludwig M, Felberbaum R, et al. Use of Cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'? Hum Reprod. 2002;17:2022-2026.
28. Engel JB, Felberbaum RE, Eilers W, et al. Clomiphene-induced LH surges and Cetrorelix. Reprod Biomed Online. 2002b;5:109-111.
29. Engel JB, Olivennes F, Fanchin R, et al. Single dose application of Cetrorelix in combination with clomiphene for friendly IVF: results of a feasibility study. Reprod Biomed Online. 2003;6:444-447.
30. Mansour R, Aboulghar M, Serour GI, et al. The use of clomiphene citrate/human menopausal gonadotrophins in conjunction with GnRH antagonist in an IVF/ICSI program is not a cost effective protocol. Acta Obstet Gynecol Scand. 2003;82:48-52.
31. Rongières-Bertrand C, Olivennes F, Righini C, et al. Revival of the natural cycles in invitro fertilization with the use of a new gonadotropin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum Reprod. 1999;14:683-688.
32. Pellinck MJ, Vogel NE, Hoek A, et al. Minimal stimulation IVF with late follicular phase administration of the GnRH antagonist Cetrorelix and concomitant substitution with recombinant FSH: a pilot study. Hum Reprod. 2005;20:642-648.
33. Pellinck MJ, Hoek A, Simons AH, et al. Efficacy of natural cycle IVF: a review of the literature. Hum Reprod Update. 2002;8:129-139.
34. Daya S, Gunby J, Hughes EG, et al. Natural cycles for in-vitro fertilization: cost-effectiveness analysis and factors influencing outcome. Hum Reprod. 1995;10:1719-1724.
35. Ubaldi FM, Rienzi L, Ferrero S, et al. Management of poor responders in IVF. Reprod Biomed Online. 2005;10:235-246.
36. Kolibianakis E, Zikopoulos K, Camus M, et al. Modified natural cycle for IVF does not offer a realistic chance of parenthood in poor responders with high day 3 FSH levels, as a last resort prior to oocyte donation. Hum Reprod. 2004;19:2545-2549.
37. Elizur SE, Aslan D, Shulman A, et al. Modified natural cycle using GnRH antagonist can be an optional treatment in poor responders undergoing IVF. J Assist Reprod Genet. 2005;22:75-79.
38. Hohmann FP, Macklon NS, Fauser BC. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab. 2003;88:166-173.
39. Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod. 2002;17:874-885.
40. Ludwig M, Katalinic A, Diedrich K. Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet. 2001;265:175-182.
41. Hernandez ER. Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod. 2000;15:1211-1216.
42. Mannaerts B, Gordon K. Embryo implantation and GnRH antagonists: GnRH antagonists do not activate the GnRH receptor. Hum Reprod. 2000;15:1882-1883.
43. Ortmann O, Weiss JM, Diedrich K. Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists. Hum Reprod. 2001;16:608-611.
44. Olivennes F, Diedrich K, Frydman R, et al; Cetrotide Multiple Dose International Study Group; Cetrotide Single Dose International Study Group. Safety and efficacy of a 3 mg dose of the GnRH antagonist Cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences. Reprod Biomed Online. 2003;6:432-438.
45. Lee TH, Wu MY, Chen HF, et al. Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin- releasing hormone antagonist administration. Fertil Steril. 2005;83:1700-1707.
46. Olivennes F, Fanchin R, Bouchard P, et al. Schedulded administration of GNRH antagonist (Cetrorelix) on day 8 of in vitro fertilization cycles: a pilot study. Hum Reprod. 1995;10:1382-1386.
47. Ludwig M, Katalinic A, Banz C, et al. Tailoring the GnRH antagonist Cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study. Hum Reprod. 2002;17:2842-2845.
48. Kolibianakis EM, Albano C, Kahn J, et al. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril. 2003;79:873-880.
49. Kolibianakis EM, Albano C, Camus M, et al. Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: effect on hormonal levels and follicular development in in vitro fertilization cycles. J Clin Endocrinol Metab. 2003;88:5632-5637.
50. Reissmann T, Felberbaum R, Diedrich K, et al. Development and applications of Luteinizing hormone-releasing antagonists in the treatment of infertility: an overview. Hum Reprod. 1995;10:1974-1981.
51. Hwang JL, Seow KM, Lin YH, et al. Ovarian stimulation by concomitant administration of Cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study. Hum Reprod. 2004;19:1993-2000.
52. Bahceci M, Ulug U, Ben-Shlomo I, et al. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. J Reprod Med. 2005;50:84-90.
53. Nikolettos N, Al-Hasani S, Felberbaum R, et al. Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. Eur J Obstet Gynecol Reprod Biol. 2001;97:202-207.
54. Akman MA, Erden HF, Tosun SB, et al. Comparison of agonistic flare-up - protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum Reprod. 2001;16:868-870.
55. Schmidt DW, Bremner T, Orris JJ, et al. A randomized prospective study of microdose leuprolide versus ganirelix in in vitro fertilization cycles for poor responders. Fertil Steril. 2005;83:1568-1571.
56. Mohamed KA, Davies WA, Allsopp J, et al. Agonist 'flare-up' versus antagonist in the management of poor responders undergoing in vitro fertilization treatment. Fertil Steril. 2005;83:331-335.
57. Cheung LP, Lam PM, Lok IH, et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod. 2005;20:616-621.
58. Kolibianakis EM, Zikopoulos K, Schiettecatte J, et al. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod. 2004;19:2490-2496.
59. Cedrin-Durnerin I, Grange-Dujardin D, Laffy A, et al. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2004;19:1979-1984.
60. Griesinger G, Schultze-Mosgau A, Dafopoulos K, et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Hum Reprod. 2005;20:1200-1206.
61. Barmat LI, Chantilis SJ, Hurst BS, et al. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH inwomen pretreated with oral contraceptives before in vitro fertilization. Fertil Steril. 2005;83:321-330.
62. Fanchin R, Salomon L, Castelo-Branco A, et al. Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Hum Reprod. 2003;18:2698-2703.
63. De Ziegler D, Brioschi PA, Benchaa C, et al. Programming ovulation in the menstrual cycle by a simple innovative approach: back to the future of assisted reproduction. Fertil Steril. 1999;72:77-82.
64. Tavaniotou A, Albano C, Smitz J, et al. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix. Hum Reprod. 2001;16:663-667.
65. Albano C, Smitz J, Tournaye H, et al. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles. Hum Reprod. 1999;14:1426-1430.
66. Albano C, Grimbizis G, Smitz J, et al. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril. 1998;70:357-359.
67. Beckers NG, Macklon NS, Eijkemans MJ, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab. 2003;88:4186-4192.
68. Ragni G, Vegetti W, Baroni E, et al. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without gonadotrophin-releasing hormone antagonist. Hum Reprod. 2001;16:2258-2262.
69. Olivennes F, Fanchin R, Bouchard P, et al. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GNRH antagonist. Fertil Steril. 1996;66:151-153.
70. Itskovitz J, Kol S, Mannaerts B. Use a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist Ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report. Hum Reprod. 2000;15:1965-1968.
71. Fauser BC, de Jong D, Olivennes F, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist Ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab. 2002;87:709-715.
72. Humaidan P, Bredkjaer HE, Bungum L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20:1213-1220.
73. Kolibianakis EM, Schultze-Mosgau A, Schroer A, et al. Griesinger GA lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005 (in press).
74. Antoine JM. GnRH antagonists in insemination: can we avoid weekends? J Gynecol Obstet Biol Reprod (Paris). 2004;33:50-52.
75. Gomez-Palomares JL, Julia B, Acevedo-Martin B, et al. Timing ovulation for intrauterine insemination with a GnRH antagonist. Hum Reprod. 2005;20:368-372.
76. Williams RS, Hillard JB, De Vane G, et al. A randomized, multicenter study comparing the efficacy of recombinant FSH vs recombinant FSH with Ganirelix during superovulation/IUI therapy. Am J Obstet Gynecol. 2004;191:648-651.